MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Bidirectional interplay between DBS and cognition in Parkinson’s disease: a systematic review

    V. Sisodia, A. Malekzadeh, E. Verwijk, P. Schuurman, R. de Bie, B. Swinnen (Amsterdam, Netherlands)

    Objective: To evaluate the evidence regarding (1) deep brain stimulation (DBS) effectiveness in case of postoperative cognitive deterioration, (2) the impact of preoperative cognition on…
  • 2024 International Congress

    Motor Impact of Fasting in Parkinson’s Disease Patients: An overview

    N. Kouki, M. Messelmani, N. Kouki, H. Derbali, J. Zaouali, R. Mrissa (tunis, Tunisia)

    Objective: To provide a literature overview of fasting impact  on motor symptoms in Parkinson disease. Background: Fasting, characterized by voluntary abstinence from food and caloric…
  • 2024 International Congress

    Combining Carbidopa/levodopa Extended-release Capsules and Immediate-release Tablets – Crucial Factors of This Economical Prescription

    Y. Tai, S. Hsu, H. Kuo (Kaohsiung City, Taiwan)

    Objective: We introduced a new way of prescribing carbidopa/levodopa extended-release (ER) capsule – combining use of immediate-release (IR) tablets. This retrospective clinical study was designed…
  • 2024 International Congress

    Deep Brain Stimulation of the Subthalamic Nuclei in Advanced Parkinson’s Disease what Effects on Motor Non-motor and Neuropsychological Functions a Monocentric Prospective Study with a 12-month Follow-up

    V. Leclercq, B. Delsaut, V. Donckels, S. Dethy (Sint-Pieters-Leeuw, Belgium)

    Objective: The aim of the study is to assess the evolution of motor symptoms (MS), non-motor symptoms (NMS) and neuropsychological functions (NF) in Parkinson's disease…
  • 2024 International Congress

    Case Report Increasing ‘On-time’ Using Mucuna pruriens Concomitantly with Traditional Levodopa/carbidopa Management

    T. Denne (United States, USA)

    Objective: Case study to see if concomitant use of the botanical Mucuna pruriens with traditional levodopa/carbidopa management could improve patient ‘off-time.’ Background: Mucuna pruriens is a pantropical legume…
  • 2024 International Congress

    ilex Paraguariensis (Yerba mate) modulates the AMPK pathway and downstream key metabolic mechanism that may explain its neuroprotective role.

    J. Ferrario, H. Hauche, L. Tschopp, T. Eidelman, M. Bordone (Buenos Aires, Argentina)

    Objective: To investigate the molecular pathways regulated by yerba mate [YM] extract and its main active compounds in a neuronal cell line as a cue…
  • 2024 International Congress

    Simulated Space Gravity Recapitulates Parkinson’s Disease Pathology in Neural Cell Model

    V. Lentini, G. Uras, A. Manca, M. El Faqir, S. Lucas, A. Schapira, A. Pantaleo (Sassari, Italy)

    Objective: This investigation centers on the potential influence of microgravity on α-synuclein aggregation, a hallmark feature of Parkinson's disease (PD) characterized by the formation of…
  • 2024 International Congress

    Identification of Pre-Diagnostic Biomarkers for Parkinson’s Disease from Plasma Proteome

    M. Ta, E. Appleton, S. Khosousi, A. Sturchio, I. Markaki, W. Paslawski, C. Blauwendraat, M. Nalls, A. Singleton, P. Svenningsson, H. Iwaki (Bethesda, USA)

    Objective: To identify pre-diagnostic biomarkers for Parkinson’s Disease (PD) from the plasma proteome. Background: The plasma proteome is a non-invasive and accessible measure to assess…
  • 2024 International Congress

    Safety and Tolerability of Bemdaneprocel in People With Parkinson’s Disease: Results up to 24 Months From a Phase 1 Study

    H. Sarva, C. Henchcliffe, A. Lozano, A. Fasano, S. Kalia, K. Yu, C. Brennan, W. Stemple, N. Abid, M. Yountz, A. Enayetallah, A. Lampron, V. Tabar (New York, USA)

    Objective: To report the safety and tolerability of bemdaneprocel in participants with Parkinson’s disease (PD) up to 24 months post transplantation. Background: Bemdaneprocel is an…
  • 2024 International Congress

    Neuroimaging Factors Differentially Associated with Pathology and Clinical Presentation

    J. Pommy, S. Bouchachi, A. Bryant, V. Thornton, C. Nguyen, J. Truelove, K. Rawson, J. Icehour, M. Knopp, C. Wright, D. Scharre (Columbus, USA)

    Objective: Examine utility of a factor analysis approach to neuroimaging data in Lewy body disease (LBD) and Alzheimer’s disease (AD). Background: Significant heterogeneity exists among patients…
  • 1
  • 2
  • 3
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley